

ASX Release

ANAGRELIDE PROJECT UPDATE

PERTH, AUSTRALIA – 7 April 2021: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, is pleased to announce the appointment of Professor Gunnar Birgegård to its Scientific Advisory Board. SUDA is developing anagrelide to be used as an adjunct therapy to treat patients with specific solid tumours and thrombocytosis (elevated platelets). The appointment represents another strong addition to the anagrelide programme.

Professor Gunnar Birgegård

Professor Gunnar Birgegård, MD, PhD, is professor of Haematology at Uppsala University, Uppsala, Sweden. His early research interests focused on iron metabolism and inflammation as well as erythropoietin pathophysiology, especially in polycythaemia vera. His research has included work on erythropoiesis and iron, mainly with regards to ferritin and inflammation, and his group was one of the first to publish a radioimmunoassay method for measuring serum erythropoietin. Professor Birgegård has also been involved in implementing erythropoietin treatment studies in autotransfusion and cancer as well as intravenous iron and Epo efficacy. He was Chairman of the Nordic Study Group for Myeloproliferative disorders and is currently involved with studies on platelet reduction therapy with anagrelide and interferon. He is also a member of Leukemia Network Work Package 9 on Myeloproliferative disorders.

Professor Birgegård has been involved in studies analysing the clinical use of anagrelide for the treatment of Essential Thrombocythemia and other Myeloproliferative Neoplasms.

SUDA's CEO and MD, Dr. Michael Baker commented: "We are very pleased that Professor Birgegård has agreed to join our Scientific Advisory Board. We are also happy with the support that the anagrelide programme is receiving from world renowned experts in the field of platelet biology and cancer. Professor Birgegård's experience using anagrelide in the clinical setting will provide valuable experience as we develop anagrelide for the treatment of metastatic disease."

For and on behalf of the Board and for further information please contact:

Dr Michael Baker

Chief Executive Officer & Managing Director

SUDA Pharmaceuticals Ltd

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit www.sudapharma.com